Antibody Targeted Amanitin Conjugates (ATACs)

Time: 10:10 am

Details:

• Evaluate Antigen-Targeted Amanitin-Conjugates (ATACs); A new class of ADCs using the payload Amanitin
• This payload introduces a novel mode of action into oncology therapy, the inhibition of RNA polymerase II
• Learn more about this technology platform that includes Amanitin supply, sitespecific conjugation, demonstrated safety profile and biomarker
• HDP-101 is the first ATAC directed against BCMA entering Phase I trials in 2020